Oral Chinese Herbal Medicine as an Adjuvant Treatment for Chemotherapy, or Radiotherapy, Induced Myelosuppression: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Table 4

Sensitivity analysis.

Analysis	Sensitivity analysis	Heterogeneity		Pooled RR (95% CI)
			Cochran Q	RR (95% CI)
WBC III-	FM	0%		0.43 (0.33–0.56)
	RM	0%		0.44 (0.34–0.58)
WBC I–	FM	49.5%		0.74 (0.67–0.81)
	RM	39.3%		0.76 (0.68–0.85)
Neutrophils III-IV	FM	42.8%		0.39 (0.27–0.58)
	RM	33.6%		0.40 (0.23–0.69)
Neutrophils I–IV	FM	60.8%		0.73 (0.63–0.85)
	RM	47.1%		0.76 (0.62–0.93)
HB III-IV	FM	0%		0.41 (0.23–0.72)
	RM	0%		0.45 (0.24–0.83)
HB I–IV	FM	81.9%		0.67 (0.58–0.78)
	RM	64.2%		0.68 (0.54–0.87)
PLT III-IV	FM	0%		0.54 (0.34–0.85)
	RM	0%		0.58 (0.36–0.93)
PLT I–IV	FM	45.2%		0.67 (0.54–0.82)
	RM	27.8%		0.69 (0.55–0.88)

III-IV = at toxic grades III-IV; I–IV = at toxic grades I–IV; FM = fixed effects model; RM = random effects model.